T2 Biosystems

T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish.
Company Growth (employees)
Lexington, US
Size (employees)
168 (est)
T2 Biosystems was founded in 2006 and is headquartered in Lexington, US

Key People at T2 Biosystems

Sarah Kalil

Sarah Kalil

Chief Operating Officer
Michael Cima

Michael Cima

Co-Founder and Director
Tom Lowery

Tom Lowery

Vice President of Diagnostics Research & Development
Rahul Dhanda

Rahul Dhanda

Vice President of Global Support Services Marketing

T2 Biosystems Office Locations

T2 Biosystems has offices in Lexington and Wilmington
Lexington, US (HQ)
101 Hartwell Ave
Wilmington, US
231 Andover St

T2 Biosystems Metrics

T2 Biosystems Financial Metrics

T2 Biosystems's revenue was reported to be $4.1 m in FY, 2016 which is a 45% increase from the previous period.

Revenue (FY, 2016)

$4.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

($54.8 m)

EBIT (FY, 2016)

($50.9 m)

Market capitalization (22-May-2017)

$101.3 m

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$73.5 m
T2 Biosystems's current market capitalization is $101.3 m.
FY, 2014FY, 2015FY, 2016


$119 k$2.8 m$4.1 m

Revenue growth, %


R&D expense

$19.8 m$25.4 m$24 m

General and administrative expense

$11 m$19.1 m$24.1 m

Operating expense total

$30.8 m$46.2 m$55 m


($30.7 m)($43.4 m)($50.9 m)

EBIT margin, %


Interest expense

($721 k)($2 m)($4.1 m)

Net Income

($31.4 m)($45.3 m)($54.8 m)
FY, 2014FY, 2015FY, 2016


$73.8 m$73.7 m$73.5 m

Accounts Receivable

$201 k$369 k$327 k


$115 k$683 k$820 k

Current Assets

$75.3 m$75.6 m$75.4 m


$2.8 m$10.7 m$13.6 m

Total Assets

$79.1 m$86.9 m$89.6 m

Accounts Payable

$735 k$1.2 m$962 k

Current Liabilities

$5.2 m$12.3 m$9.9 m

Additional Paid-in Capital

$156.6 m$195.8 m$243 m

Retained Earnings

($103.6 m)($148.9 m)($203.7 m)

Total Equity

$53 m$46.9 m$39.3 m

Financial Leverage

1.5 x1.9 x2.3 x
FY, 2014FY, 2015FY, 2016

Net Income

($31.4 m)($45.3 m)($54.8 m)

Depreciation and Amortization

$691 k$1.5 m$2.3 m

Accounts Receivable

($201 k)($168 k)$42 k


($1.2 m)($568 k)

Accounts Payable

($208 k)$177 k($61 k)

Cash From Operating Activities

$43.7 m($187 k)($46.4 m)

Purchases of PP&E

($2.1 m)($8 m)($5.5 m)

Cash From Investing Activities

($2.1 m)($7.9 m)($5.5 m)

Cash From Financing Activities

$73.9 m$45.2 m$51.8 m

Interest Paid

$515 k$1.5 m$2.7 m
Y, 2016

Financial Leverage

2.3 x

T2 Biosystems Operating Metrics

FY, 2016



Patents Issued


Patent Applications


T2 Biosystems Market Value History

T2 Biosystems Online Presence

T2 Biosystems Company Life

You may also be interested in